Cilengitide. Oncolytic, angiogenesis inhibitor, integrin αvβ3,αvβ5 antagonist

Drugs of the Future

Volumn 25, Issue 7, 2000, Pages 674-678

  Sorbera, L A ^a   Graul, A ^a   Castaner, J ^a  

^a PROUS SCIENCE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTIBODY; ANTINEOPLASTIC AGENT; CILENGITIDE; EMD 85189; HYBRID PROTEIN; INTEGRIN; INTERLEUKIN 2; INTERLEUKIN 2 FUSION PROTEIN ANTIBODY; OVALBUMIN; RECOMBINANT FIBROBLAST GROWTH FACTOR; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER; CLINICAL TRIAL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; GLIOBLASTOMA; HUMAN; LIVER METASTASIS; MEDULLOBLASTOMA; MELANOMA; NEUROBLASTOMA; NONHUMAN; RHEUMATOID ARTHRITIS;

EID: 0033807315     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2000.025.07.586439     Document Type: Article

References (21)

1. AE-941
2. Integrin αvβ3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels
3. Integrin αvβ3 rescues melanoma cells from apoptosis in three-dimensional dermal collagen
4. Anchorage dependence, integrins, and apoptosis
5. Integrin distribution in malignant melanoma: Association of the β3 subunit with tumor progression
6. Altered integrin expression in adenocarcinoma of the breast. Analysis by in situ hybridization
7. Arg-Gly-Asp constrained within cyclic pentapeptides. Strong and selective inhibitors of cell adhesion to vitronectin and laminin fragment P1
8. Conformation/activity studies of rationally designed potent anti-adhesive RGD peptides
9. Dynamic forcing, a method for evaluating activity and selectivity profiles of RGD peptides
10. Structural and functional aspects of RGD-containing cyclic pentapeptides as highly potent and selective integrin αvβ3 antagonists
11. Stereoisomerism and biological activity of the selective and superactive αvβ3 integrin inhibitor cyclo(-RGDfV-) and its retro-inverso peptide
12. Cyclic RGD peptides containing beta-turn mimetics
13. Stereoisomeric peptide of the αvβ3 integrin for a new cancer therapy
14. N-Methylated cyclic RGD peptides as highly active and selective αvβ3 integrin antagonists
15. Decreased angiogenesis and arthritic disease in rabbits treated with an αvβ3 antagonist
16. Antagonist to αv-integrin inhibits growth of orthotopically but not heterotopically transplanted brain tumors
17. Synergy between an antiangiogenic integrin αv antagonist and an antibody-cytokine fusion protein eradicates spontaneous tumor metastases
18. Evaluation of absorption enhancement for a potent cyclopeptidic αvβ3-antagonist in a human intestinal cell line (Caco-2)
19. Phase I and pharmacologic study of EMD 121974, an αvβ3 and αvβ5 integrin inhibitor that perturbs tumor angiogenesis, in patients with solid tumors